

Literatur zum Artikel:

Möglichkeiten und Grenzen der Suizidprävention

von Prof. Dr. med. Ute Lewitzka, Dipl.-Pflegerin Christian Petzold und Dr. phil. Dipl.-Ing. Katharina König

- [1] Statistisches Bundesamt. Todesursachen. Destatis 2025; Im Internet: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/_inhalt.html; Stand: 04.11.2025
- [2] Bundesärztekammer. Hinweise der Bundesärztekammer zum ärztlichen Umgang mit Suizidalität und Todeswünschen nach dem Urteil des Bundesverfassungsgerichts zu § 217 StGB. Dtsch Arztebl International 2021; 29–30
- [3] Bundesministerium für Gesundheit. Nationale Suizidpräventionsstrategie. 2024
- [4] Stene-Larsen K, Reneflot A. Contact with primary and mental health care prior to suicide: A systematic review of the literature from 2000 to 2017. Scand J Public Health 2019; 47: 9–17. doi:10.1177/1403494817746274
- [5] Hawton K, Lascelles K, Pitman A, et al. Assessment of suicide risk in mental health practice: shifting from prediction to therapeutic assessment, formulation, and risk management. The Lancet Psychiatry 2022; 9: 922–928. doi:10.1016/S2215–0366(22)00232–2
- [6] Seyedsalehi A, Bailey J, Ogonah MGT, et al. Prediction models for self-harm and suicide: a systematic review and critical appraisal. BMC Med 2025; 23: 549. doi:10.1186/s12916–025–04367–6
- [7] Teismann T, Forkmann T, Glaesmer H. Risikoabschätzung bei suizidalen Patienten: Geht das überhaupt? Verhaltenstherapie 2019; 29: 80–84. doi:10.1159/000493887
- [8] Brand C, Haas C, Dreischulte T, et al. Behandlung suizidaler Patienten in der Hausarztpraxis: Eine qualitative Studie zu Hindernissen und erleichternden Faktoren. Nervenarzt 2025; doi:10.1007/s00115–025–01826–6
- [9] Teismann T, Forkmann T. Ambivalenzmodell der Suizidalität (ABS-Modell): Ein Verstehens- und Orientierungsmodell für die Behandlung suizidaler Personen. Verhaltenstherapie 2024; 34: 85–92. doi:10.1159/000540043
- [10] AWMF. S3-Leitlinie Unipolare Depression, Langfassung, Version 3.2. 2020;
- [11] Polihronis C, Cloutier P, Kaur J, et al. What’s the harm in asking about suicide-related behaviors and self-harm with quality appraisal. Archives of Suicide Research 2022; 26: 325–347. doi:10.1080/13811118.2020.1793857
- [12] Fachkräfte – Deutsche Gesellschaft für Suizidprävention e. V. Im Internet: <https://www.suizidprophylaxe.de/fachkraefte/>; Stand: 10.04.2026
- [13] Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review. The Lancet Psychiatry 2016; 3: 646–659. doi:10.1016/S2215–0366(16)30030-X
- [14] Steeg S, Ledden S, Marzano L, et al. Effectiveness of suicide means restriction: an overview of systematic reviews. BMJ Ment Health 2025; 28: e302069. doi:10.1136/bmjment-2025–302069
- [15] Too LS, Spittal MJ, Bugeja L, et al. The association between mental disorders and suicide: A systematic review and meta-analysis of record linkage studies. Journal of Affective Disorders 2019; 259: 302–313. doi:10.1016/j.jad.2019.08.054
- [16] Lewitzka U, Knappe S. Suizidalität. PSYCH up2date 2021; 15: 419–432. doi:10.1055/a-1211–7017
- [17] Tai A, Pincham H, Basu A, et al. Meta-analysis of risk factors for suicide after psychiatric discharge and meta-regression of the duration of follow-up. Aust N Z J Psychiatry 2025; 59: 679–691. doi:10.1177/00048674251348372
- [18] Homan S, Marciniak MA, Michel S, et al. Effectiveness of brief interventions and contacts after suicide attempt: a systematic review and meta-analysis. eClinicalMedicine 2026; 93: 103824. doi:10.1016/j.eclinm.2026.103824
- [19] Preventing Suicide: a Resource for Media Professionals, 2023 Update. 1st ed. Geneva: World Health Organization; 2023
- [20] Oexle N, Mayer L, Rüscher N. Suicide stigma and suicide prevention. Nervenarzt 2020; 779–784. doi:10.1007/s00115–020–00961–6
- [21] Zimmermann C, Strohmaier S, Herkner H, et al. Suicide rates among physicians compared with the general population in studies from 20 countries: gender stratified systematic review and meta-analysis. BMJ 2024; e078964. doi:10.1136/bmj-2023–078964

- [22] Frank E, Sen S, Guille C. Female Physician Suicide Compared to the General Population. *JAMA Psychiatry* 2025; 82: 440. doi:10.1001/jamapsychiatry.2024.4786
- [23] Garcia CF-P, Cantero-Garcia M, Dorta-Afonso D, et al. Factors associated with suicidal ideation in healthcare personnel: a systematic review. *Front Psychol* 2025;16: 1717231. doi:10.3389/fpsyg.2025.1717231
- [24] Petrie K, Crawford J, Shand F, et al. Workplace stress, common mental disorder and suicidal ideation in junior doctors. *Internal Medicine Journal* 2021; 51: 1074–1080. doi:10.1111/imj.15124
- [25] PSU-HELPLINE. PSU Akut eV HELPLINE. Im Internet: <https://psu-helpline.de/>; Stand: 10.04.2026
- [26] Yu AY (Annie), Stergiopoulos E, Sukhera J, et al. A qualitative analysis of the barriers and facilitators to physicians and trainees seeking help for suicidality. *CMAJ* 2026; 198: E238–E248. doi:10.1503/cmaj.250200
- [27] Petrie K, Gregory M, Collins DAJ, et al. A systematic review and meta-analysis of interventions to reduce or prevent symptoms of common mental disorders and suicidality in physicians. *Nat Mental Health* 2025; 3: 838–851. doi:10.1038/s44220-025-00450-2
- [28] Jupina M, Mercer M, Weleff J, et al. Prevalence of Patient Suicide and Its Impact on Health Care Professionals: A Systematic Review. *PS* 2024; 75: 999–1008. doi:10.1176/appi.ps.20230351
- [29] Suizidpräventionsgesetz (SuizidPrävG-E). BMG. Im Internet: <https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/gesetz-zur-staerkung-der-nationalen-suizidpraevention>; Stand: 10.04.2026

Literatur zum Artikel:

Leitlinie systemische Sklerose

von Dr. med. Nils Schulz und Prof. Dr. med. Ulf Müller-Ladner

- [1] Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Colic J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. *Ann Rheum Dis*. 2025;84:29–40, epub
- [2] S2k-Leitlinie Diagnostik und Therapie der systemischen Sklerose. AWMF Registernummer 060 – 014, 2025
- [3] Andreasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. *Ann Rheum Dis*. 2014;73(10):1788–92.
- [4] Butt SA, Jeppesen JL, Fuchs C, Mogensen M, Engelhart M, Torp-Pedersen C, et al. Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. *BMC Rheumatol*. 2018;2:36.
- [5] Schinke S, Riemekasten G. [Systemic sclerosis]. *Internist (Berl)*. 2019;60(12):1251–69.
- [6] Assassi S, Mayes MD. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? *Curr Opin Rheumatol*. 2013;25(6):686–91.
- [7] Huchala E MC, Bruni C. *EULAR Textbook on Systemic Sclerosis – Second Edition 2019*.
- [8] Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. *Ann Rheum Dis*. 2017;76(11):1897–905.
- [9] Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. *Arthritis Rheum*. 2008;58(12):3902–12.
- [10] Bellando-Randone S, Del Galdo F, Lepri G, Minier T, Huscher D, Furst DE, et al. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). *Lancet Rheumatol*. 2021;3(12):e834–e43.
- [11] Hanitsch LG, Burmester GR, Witt C, Hunzelmann N, Genth E, Krieg T, et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations—an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. *Rheumatology (Oxford)*. 2009;48(1):70–3.
- [12] van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis Rheum*. 2013;65(11):2737–47.
- [13] Hoffmann-Vold AM, Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, et al. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. *Am J Respir Crit Care Med*. 2019;200(10):1258–66.
- [14] Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Lauzun D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. *Arthritis Rheum*. 2011;63(11):3522–30.
- [15] Mouthon L, Bussone G, Berezne A, Noel LH, Guillevin L. Scleroderma renal crisis. *J Rheumatol*. 2014;41(6):1040–8.
- [16] Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. *Arthritis Rheum*. 2001;44(6):1351–8.
- [17] van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. *Br J Rheumatol*. 1996;35(4):364–72.
- [18] Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIREs): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. *Lancet Rheumatol*. 2022;4(8):e546–e55.

- [19] Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. *Lancet Respir Med*. 2023;11(1):45–54.
- [20] Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. *Lancet*. 2016;387(10038):2630–40.
- [21] Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. *Am J Respir Crit Care Med*. 2022;205(6):674–84.
- [22] Connolly KL, Griffith JL, McEvoy M, Lim HW. Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients. *Photodermatol Photoimmunol Photomed*. 2015;31(6):289–95.
- [23] Kreuter A, Breuckmann F, Uhle A, Brockmeyer N, Von Kobyletzki G, Freitag M, et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. *J Am Acad Dermatol*. 2004;50(5):740–7.
- [24] Cribier B, Faradji T, Le Coz C, Oberling F, Grosshans E. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. *Dermatology*. 1995;191(1):25–31.
- [25] Knobler RM, French LE, Kim Y, Bisaccia E, Graninger W, Nahavandi H, et al. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. *J Am Acad Dermatol*. 2006;54(5):793–9.
- [26] Traineau H, Aggarwal R, Monfort JB, Senet P, Oddis CV, Chizzolini C, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. *J Am Acad Dermatol*. 2020;82(2):317–25.
- [27] von Hodenberg C, Neufeld M, Wohlrab J, Meyer D, Ehrchen J, Sunderkotter C. [Not Available]. *J Dtsch Dermatol Ges*. 2020;18(10):1181–3.
- [28] Gauffenic A, Ratsimbazafy V, Ostertag A, Linglart A, Bourrat E, Leroy C, et al. Effectiveness of topical sodium thiosulfate for ectopic calcifications and ossifications. Results of the CATSS-O study. *Semin Arthritis Rheum*. 2023;63:152306.
- [29] Merlino G, Germano S, Carlucci S. Surgical management of digital calcinosis in CREST syndrome. *Aesthetic Plast Surg*. 2013;37(6):1214–9.
- [30] Manohara R, Breusch SJ. Assessment and Surgical Treatment of Calcinosis of the Shoulder Associated with CREST Syndrome. *Case Rep Rheumatol*. 2016;2016:9759182.
- [31] Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. The Cochrane database of systematic reviews. 2017;12(12):Cd000467.
- [32] Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, et al. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. *Seminars in arthritis and rheumatism*. 2019;48(4):686–93.
- [33] Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. The Cochrane database of systematic reviews. 2000;1998(2):Cd000953.
- [34] Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. *Arthritis Care Res (Hoboken)*. 2013;65(9):1460–71.
- [35] Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. *Rheumatology (Oxford)*. 2010;49(12):2420–8.
- [36] Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jengo P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. *Ann Rheum Dis*. 2016;75(6):1009–15.
- [37] Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis*. 2011;70(1):32–8.
- [38] Bonifazi M, Sverzellati N, Negri E, Jacob J, Egashira R, Moser J, et al. Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. *Eur Respir J*. 2020;56(1).
- [39] Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. *Am J Respir Crit Care Med*. 2002;165(12):1581–6.

- [40] Doyle TJ, Dellaripa PF. Lung Manifestations in the Rheumatic Diseases. *Chest*. 2017;152(6):1283–95.
- [41] Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. *Clin Epidemiol*. 2019;11:257–73.
- [42] Kreuter M, Behr J, Bonella F, Costabel U, Gerber A, Hamer OW, et al. [Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases]. *Pneumologie*. 2023;77(5):269–302.
- [43] Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggarr R, et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. *Respir Res*. 2023;24(1):6.
- [44] Alex G, Shanoj KC, Varghese DR, Sageer Babu AS, Reji R, Shenoy PD. Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: A crossover trial. *Semin Arthritis Rheum*. 2023;63:152270.
- [45] Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2020;8(10):963–74.
- [46] Al Oweidat KS, Abdulelah AA, Toubasi AA, Abdulelah M, Alatteili NZ, Abdulelah ZA. The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review. *Can Respir J*. 2025:1682546.
- [47] Behr J, Gunther A, Ammenwerth W, Bittmann I, Bonnet R, Buhl R, et al. [German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. *Pneumologie*. 2013;67(2):81–111.
- [48] Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. *Eur Respir J*. 2011;37(4):743–6.
- [49] Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, et al. Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. *J Heart Lung Transplant*. 2018;37(7):903–11.
- [50] Crespo MM, Bermudez CA, Dew MA, Johnson BA, George MP, Bhamra J, et al. Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes. *Ann Am Thorac Soc*. 2016;13(6):784–92.
- [51] Weatherald J, Montani D, Jevnikar M, Jais X, Savale L, Humbert M. Screening for pulmonary arterial hypertension in systemic sclerosis. *Eur Respir Rev*. 2019;28(153).
- [52] Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. *Ann Rheum Dis*. 2007;66(7):940–4.
- [53] Young A, Moles VM, Jaafar S, Visovatti S, Huang S, Vummidi D, Nagaraja V, McLaughlin V, Khanna D. Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. *Arthritis Rheumatol*. 2021 Sep;73(9):1731–1737.
- [54] Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. *J Rheumatol*. 2006;33(6):1113–6.
- [55] Derk CT, Rasheed M, Spiegel JR, Jimenez SA. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. *J Rheumatol*. 2005;32(4):637–41.
- [56] Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC, et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. *Scand J Rheumatol*. 2012;41(1):44–9.
- [57] Nassar M, Ghernautan V, Nso N, Nyabera A, Castillo FC, Tu W, et al. Gastrointestinal involvement in systemic sclerosis: An updated review. *Medicine (Baltimore)*. 2022;101(45):e31780.
- [58] Frieling T. Sklerodermie. *Gastroenterologie*. 2022(17):296–307.
- [59] Cheah JX, Khanna D, McMahan ZH. Management of scleroderma gastrointestinal disease: Lights and shadows. *J Scleroderma Relat Disord*. 2022;7(2):85–97.
- [60] Shreiner AB, Murray C, Denton C, Khanna D. Gastrointestinal Manifestations of Systemic Sclerosis. *J Scleroderma Relat Disord*. 2016;1(3):247–56.
- [61] Keane N, Ghannam A, Fragkos KC, Rahman F. Oral, enteral and parenteral nutritional therapies in scleroderma: A systematic review. *Clin Nutr ESPEN*. 2022;51:174–84.
- [62] McMahan ZH, Kulkarni S, Chen J, Chen JZ, Xavier RJ, Pasricha PJ, et al. Author Correction: Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. *Nat Rev Rheumatol*. 2023;19(3):191.
- [63] McMahan ZH, Kulkarni S, Chen J, Chen JZ, Xavier RJ, Pasricha PJ, et al. Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. *Nat Rev Rheumatol*. 2023;19(3):166–81.

- [64] Tandaipan J, Guillén-Del-Castillo A, Simeón-Aznar CP, Carreira PE, De la Puente C, Narváez J, Lluch J, Rubio-Rivas M, Alegre-Sancho JJ, Bonilla G, Moriano C, Casafont-Sole I, García-Vicuña R, Ortiz-Santamaría V, Riera E, Atienza-Mateo B, Blanco R, Galisteo C, Gonzalez-Martin JJ, Pego-Reigosa JM, Pros A, Heredia S, Castellví I. Immunoglobulins in systemic sclerosis management. A large multicenter experience. *Autoimmun Rev.* 2023 Nov;22(11):103441.
- [65] Koczanowski S, Morrisroe K, Fairley J, Nikpour M, Oon S, Brown Z. Role of intravenous immunoglobulins in systemic sclerosis (SSc): systematic literature review. *Semin Arthritis Rheum.* 2024 Oct;68:152471.
- [66] Hammer HF, Fox MR, Keller J, Salvatore S, Basilisco G, Hammer J, et al. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. *United European Gastroenterol J.* 2022;10(1):15–40.
- [67] Marie I, Ducrotte P, Denis P, Menard JF, Levesque H. Small intestinal bacterial overgrowth in systemic sclerosis. *Rheumatology (Oxford).* 2009;48(10):1314–9.
- [68] McMahan ZH, Paik JJ, Wigley FM, Hummers LK. Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis. *Arthritis Care Res (Hoboken).* 2018;70(9):1385–92.
- [69] McMahan ZH, Tucker AE, Perin J, Volkmann ER, Kulkarni S, Ziessman HA, et al. Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis. *Arthritis Care Res (Hoboken).* 2022;74(3):442–50.
- [70] Parodi A, Sessarego M, Greco A, Bazzica M, Filaci G, Setti M, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. *Am J Gastroenterol.* 2008;103(5):1257–62.
- [71] Pittman N, Rawn SM, Wang M, Masetto A, Beattie KA, Larche M. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. *Rheumatology (Oxford).* 2018;57(10):1802–11.
- [72] Polkowska-Pruszyńska B, Gerkowicz A, Szczepanik-Kulak P, Krasowska D. Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature. *Arch Dermatol Res.* 2019;311(1):1–8.
- [73] Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. *Am J Gastroenterol.* 2017;112(5):775–84.
- [74] Sawadpanich K, Soison P, Chunlertrith K, Mairiang P, Sukeepaisarnjaroen W, Sangchan A, et al. Prevalence and associated factors of small intestinal bacterial overgrowth among systemic sclerosis patients. *Int J Rheum Dis.* 2019;22(4):695–9.
- [75] Subklewe M, Magno G, Gebhardt C, Bücklein V, Szelinski F, Arévalo HJR, Hänel G, Dörner T, Zugmaier G, von Bergwelt-Baildon M, Skapenko A, Schulze-Koops H. Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study. *Eur J Cancer.* 2024 Jun;204:114071.
- [76] Sakkas LI, Katsiari C, Syrmou V, Chikanza IC. CAR-T cells in systemic sclerosis. *Clin Rheumatol* 2026;45:651–656, epub.
- [77] Sieiro Santos C, Del Galdo F. New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025. *RMD Open.* 2025;11:e005776, epub.
- [78] Tedeschini E, Pingani L, Simoni E, Ferrari D, Giubbarelli C, Giuggioli D, et al. Correlation of articular involvement, skin disfigurement and unemployment with depressive symptoms in patients with systemic sclerosis: a hospital sample. *Int J Rheum Dis.* 2014;17(2):186–94.
- [79] Heyne S, Haufe E, Beissert S, Schmitt J, Gunther C. Determinants of Depressive Symptoms, Quality of Life, Subjective Health Status and Physical Limitation in Patients with Systemic Sclerosis. *Acta Derm Venereol.* 2023;103:adv6502.
- [80] Kwakkenbos L, Arthurs E, van den Hoogen FH, Hudson M, van Lankveld WG, Baron M, et al. Cross-language measurement equivalence of the Center for Epidemiologic Studies Depression (CES-D) scale in systemic sclerosis: a comparison of Canadian and Dutch patients. *PLoS One.* 2013;8(1):e53923.
- [81] Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. *J Rheumatol.* 2003;30(8):1782–7.
- [82] Dai L, Xu D, Li X, Huang S, Duan X, Zheng A, et al. Reproductive health in female patients with systemic sclerosis: a cross-sectional study. *Rheumatology (Oxford).* 2024;63(7):1911–6.

- [83] Barilaro G, Castellanos A, Gomez-Ferreira I, Lledo GM, Della Rocca C, Fernandez-Blanco L, et al. Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center. *Arthritis Res Ther.* 2022;24(1):91.
- [84] Blagojevic J, AlOdhaibi KA, Aly AM, Bellando-Randone S, Lepri G, Bruni C, et al. Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. *J Rheumatol.* 2020;47(6):881–7.
- [85] Tombetti E, RV, Betelli M, et al. Op0175: International Multicentric Prospective Study on Pregnancy in Systemic Sclerosis (IMPRESS-2). *EULAR: Ann Rheum Dis.* 2021;80(Suppl 1):105–105.
- [86] Taraborelli M, Ramoni V, Brucato A, Airo P, Bajocchi G, Bellisai F, et al. Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. *Arthritis Rheum.* 2012;64(6):1970–7.
- [87] Steen VD. Pregnancy in women with systemic sclerosis. *Obstet Gynecol.* 1999;94(1):15–20.

Literatur zum Artikel:

Geschlechtsspezifische Ungleichbehandlung in der Medizin am Beispiel des Herzinfarkts

Eine medizinethische Perspektive

von Dr. med. Antonia Sahn, M.A.

- [1] Healy B. The Yentl syndrome. *N Engl J Med*. 1991;325(4): 274–6.
- [2] Minissian MB, Mehta PK, Hayes SN, Park K, Wei J, Bairey Merz CN, et al. Ischemic heart disease in young women: JACC review topic of the week. *J Am Coll Cardiol*. 2022; 80(10):1014–22. doi:10.1016/j.jacc.2022.01.057.
- [3] Kuehnemund L, Lange SA, Feld J, Padberg JS, Fischer AJ, Makowski L, et al. Sex disparities in guideline-recommended therapies and outcomes after ST-elevation myocardial infarction in a contemporary nationwide cohort of patients over an eight-year period. *Atherosclerosis*. 2023;375:30–7. doi:10.1016/j.atherosclerosis.2023.05.007.
- [4] Veenis JF, Rocca HB, Linssen GCM, Erol-Yilmaz A, Pronk ACB, Engelen DJM, et al. Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. *Eur J Prev Cardiol*. 2021;28(9):957–65. doi:10.1177/2047487320923185.
- [5] Miller AL, Simon D, Roe MT, Kontos MC, Diercks D, Amsterdam E, et al. Comparison of delay times from symptom onset to medical contact in Blacks versus Whites with acute myocardial infarction. *Am J Cardiol*. 2017;119(8):1127–34. doi:10.1016/j.amjcard.2016.12.021.
- [6] Garth G. Racial and ethnic differences in acute coronary syndrome and myocardial infarction within the United States: from demographics to outcomes. *Clin Cardiol*. 2016;39(5):299–306. doi:10.1002/clc.22524.
- [7] Mehta LS, Velarde GP, Lewey J, Sharma G, Bond RM, Navas-Acien A, et al. Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association. *Circulation*. 2023; 147(19):1471–87. doi:10.1161/CIR.0000000000001139.
- [8] Nationaler Diskriminierungs- und Rassismusmonitor. Rassismus und seine Symptome [Internet]. Berlin: DeZIM-Institut; [cited 2026 Feb 21]. Available from: <https://www.rassismusmonitor.de/publikationen/rassismus-und-seine-symptome/>
- [9] Tetzlaff J, Geyer S, Westhoff-Bleck M, Sperlich S, Epping J, Tetzlaff F. Social inequalities in mild and severe myocardial infarction: how large is the gap in health expectancies? *BMC Public Health*. 2021;21:259. doi:10.1186/s12889-021-10236-7.
- [10] Fricker M. *Epistemic injustice: power and the ethics of knowing*. Oxford: Oxford University Press; 2007.
- [11] Zhang L, Losin EAR, Ashar YK, Koban L, Wager TD. Gender biases in estimation of others' pain. *J Pain*. 2021;22(9):1048–59. doi:10.1016/j.jpain.2021.03.001.
- [12] Gurven MD, Lieberman DE. WEIRD bodies: mismatch, medicine and missing diversity. *Evol Hum Behav*. 2020 Sep;41(5):330–340. doi:10.1016/j.evolhumbehav.2020.04.001.
- [13] AlShebli BK, Rahwan T, Woon WL. The preeminence of ethnic diversity in scientific collaboration. *Nat Commun*. 2018;9:5163. doi:10.1038/s41467-018-07634-8.
- [14] Mital R, Bayne J, Rodriguez F, Ovbiagele B, Bhatt DL, Albert MA. Race and ethnicity considerations in patients with coronary artery disease and stroke: JACC Focus Seminar 3/9. *J Am Coll Cardiol*. 2021;78(24):2483–92. doi:10.1016/j.jacc.2021.05.051.
- [15] Khan SS, Beach LB, Yancy CW. Sex-based differences in heart failure: JACC Focus Seminar 7/7. *J Am Coll Cardiol*. 2022;79(15):1530–41. doi:10.1016/j.jacc.2022.02.013.
- [16] Huded CP, Johnson M, Kravitz K, Menon V, Abdallah M, Gullett TC, et al. Four-step protocol for disparities in STEMI care and outcomes in women. *J Am Coll Cardiol*. 2018;71(19):2122–32. doi:10.1016/j.jacc.2018.02.039.
- [17] United Nations. *Universal Declaration of Human Rights*. New York: United Nations; 1948. Article 25.

Literatur zum Artikel:

Konflikt, Pandemie, Klinikabbau

Das Dreifachrisiko, das Deutschland unterschätzt: „Bedingt einsatzbereit“ revisited

von Prof. Dr. med. Dr. med. dent. Ernst Hanisch und Prof. Dr. med. Hans-Bernd Hopf

- [1] North Atlantic Treaty Organization (NATO). Keynote speech by NATO Secretary General Mark Rutte and moderated discussion with German Foreign Minister Johann Wadephul [Internet]. Brussels: NATO; 2025 Dec 11 [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.nato.int/en/news-and-events/events/transcripts/2025/12/11/keynote-speech-by-nato-secretary-general-mark-rutte-and-moderated-discussion-with-the-minister-for-foreign-affairs-of-germany-johann-wadephul>
Kurzlink: <https://t1p.de/4lvla>
- [2] North Atlantic Treaty Organization (NATO). Building a better NATO. Speech by NATO Secretary General Mark Rutte at Chatham House, London, United Kingdom [Internet]. Brussels: NATO; 2025 Jun 10 [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.nato.int/en/news-and-events/events/transcripts/2025/06/10/building-a-betternato>
Kurzlink: <https://t1p.de/xko9q>
- [3] Danish Defence Intelligence Service (DDIS). Intelligence Outlook 2024 [Internet]. Copenhagen: DDIS; 2024 [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.fe-ddis.dk/globalassets/fe/dokumenter/2024/intelligenceoutlook.pdf> oder via Kurzlink: <https://t1p.de/2pfgn>
- [4] Danish Defence Intelligence Service (DDIS). Intelligence Outlook 2025 [Internet]. Copenhagen: DDIS; 2025 [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.fe-ddis.dk/globalassets/fe/dokumenter/2025/-fe-intelligenceoutlook-25-.pdf> oder via Kurzlink: <https://t1p.de/herg9>
- [5] Bundeswehr. Operationsplan Deutschland [Internet]. Berlin: Bundeswehr; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.bundeswehr.de/de/organisation/operativesfuehrungskommando-der-bundeswehr/auftrag-und-aufgaben/operationsplandeutschland> oder via Kurzlink: <https://t1p.de/dr7qx>
- [6] Statistisches Bundesamt (Destatis). Krankenhäuser 2024: Zahl der Kliniken um 33 gesunken (Pressemitteilung Nr. 398) [Internet]. Wiesbaden: Destatis; 2025 Nov 6 [Zugriff am 2026 Apr 7]. Verfügbar unter: https://www.destatis.de/DE/Presse/Pressemitteilungen/2025/11/PD25_398_231.html
- [7] Statistisches Bundesamt (Destatis). Eckzahlen der Krankenhäuser [Internet]. Wiesbaden: Destatis; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Krankenhaeuser/Tabellen/eckzahlen-krankenhaeuser.html>
- [8] Bundesministerium für Gesundheit (BMG). Krankenhausreform [Internet]. Berlin: BMG; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.bundesgesundheitsministerium.de/themen/krankenhaus/krankenhausreform.html>
- [9] Bundesministerium für Gesundheit (BMG). KHVVG Folgenabschätzung – Abschlussbericht [Internet]. Berlin: BMG; 2024 [Zugriff am 2026 Apr 7]. Verfügbar unter: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Forschungsberichte/KHVVG_Folgenabschaetzung_Abschlussbericht.pdf oder via Kurzlink: <https://t1p.de/ygipj>
- [10] Robert Koch-Institut (RKI). Nationale Pandemieplanung [Internet]. Berlin: RKI; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://www.rki.de/DE/Themen/Infektionskrankheiten/Preparedness-und-Response/Pandemieplanung/nationale-pandemieplanung-node.html> oder via Kurzlink: <https://t1p.de/lehv1>
- [11] Robert Koch-Institut (RKI). GrippeWeb: Aktueller Wochenbericht [Internet]. Berlin: RKI; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: https://www.rki.de/DE/Themen/Forschung-und-Forschungsdaten/Sentinelns-Surveillance-Panel/GrippeWeb/Aktueller-Wochenbericht/Wochenbericht_aktuell.html
- [12] World Health Organization (WHO). Pandemic influenza risk management: a WHO guide to inform and harmonize national and international pandemic preparedness and response [Internet]. Geneva: WHO; 2017 [Zugriff am 2026 Apr 7]. Verfügbar unter: <https://apps.who.int/iris/handle/10665/259893>
- [13] Eurostat. Temporary protection for persons fleeing Ukraine – monthly statistics [Internet]. Luxembourg: European Commission; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: https://ec.europa.eu/eurostat/statisticsexplained/index.php/Temporary_protection_for_persons_fleeing_Ukraine_-_monthly_statistics oder via Kurzlink: <https://t1p.de/6ck5o>

- [14] Die Bundesregierung. ExpertInnenrat „Gesundheit und Resilienz“: 7. Stellungnahme [Internet]. Resilienz und Gesundheitssicherheit im Krisen- und Bündnisfall. Berlin: Presse- und Informationsamt der Bundesregierung; 2024 Dec 10 [Zugriff am 2026 Apr 7]. Verfügbar via Kurzlink: <https://t1p.de/n7hvj>
- [15] Bundesrepublik Deutschland. Grundgesetz für die Bundesrepublik Deutschland: Art. 73 [Internet]. Berlin: Bundesministerium der Justiz; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: https://www.gesetze-im-internet.de/gg/art_73.html
- [16] Bundesministerium des Innern und für Heimat (BMI). Gefahrenabwehr und Katastrophenschutz [Internet]. Berlin: BMI; o. J. [Zugriff am 2026 Apr 7]. Verfügbar unter: [https://www.bmi.bund.de/DE/themen/bevoelkerungsschutz/zivil-und-katastrophenschutz/ Gefahrenabwehr-und-katastrophenschutz- node.html](https://www.bmi.bund.de/DE/themen/bevoelkerungsschutz/zivil-und-katastrophenschutz/ Gefahrenabwehr-und-katastrophenschutz-node.html) oder via Kurzlink: <https://t1p.de/ic5wi>
- [17] Lau Tobias: Krisenfeste Strukturen schaffen. Dtsch Arztebl. 2026;123(7):A372-A377.

Ungültige Arztausweise

Folgende Arztausweise sind verloren und hiermit ungültig:

Arztausweis-Nr. 060342218 ausgestellt am 16.09.2024 für Felix Bortz Nottwil, Schweiz

eHBA-Nr. 80276001081611042489 ausgestellt am 21.04.2021 für Dr. med. Johanna Bruckmeir, Heppenheim

Arztausweis-Nr. 060367907 ausgestellt am 14.02.2025 für Francesco-Mariano Bruno, Schwalbach

Arztausweis-Nr. 060258459 ausgestellt am 06.03.2023 für Silke Figge, Schwalmstadt

Arztausweis-Nr. 060383738 ausgestellt am 14.05.2025 für Georg Filipowicz, Frankfurt

Arztausweis-Nr. 060456539 ausgestellt am 24.09.2025 für MUDr./Univ. Kosice Katarina Gabriel, Petersberg

Arztausweis-Nr. 060202382 ausgestellt am 13.07.2022 für Patrick Haan, Kassel

Arztausweis-Nr. 060216095 ausgestellt am 19.09.2022 für Johanna Keller, Kassel

Arztausweis-Nr. 060291183 ausgestellt am 24.11.2023 für Reiner Krause, Zwingenberg

Arztausweis-Nr. 060333835 ausgestellt am 26.07.2024 für Dr. med. Mascha Manegold, Frankfurt

Arztausweis-Nr. 060345791 ausgestellt am 08.10.2024 für Natalie Mann-Borchert, Frankfurt

Arztausweis-Nr. 060309716 ausgestellt am 06.03.2024 für Irene Poensgen, Oppenheim

Arztausweis-Nr. 060302352 ausgestellt am 30.01.2024 für Dr. med. Ulrike Siepmann, Wiesbaden

Arztausweis-Nr. 060262502 ausgestellt am 05.04.2023 für Dr. med. Rudolf Völker, Rodgau

Arztausweis-Nr. 060552081 ausgestellt am 16.03.2026 für Chiara Katharina Zimmermann, Pulheim Ot Brauweiler